<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="italic;} Case Rep Infect DisCase Rep Infect DisCRIIDCase Reports in" exact="Infectious" post="Diseases2090-66252090-6633Hindawi pmcid: 6973187 pmid: 31970003 doi: 10.1155/2020/5981289 : Case"/>
 <result pre="31970003 doi: 10.1155/2020/5981289 : Case Report Successful Treatment of Adenovirus" exact="Infection" post="with Brincidofovir in an Immunocompromised Patient after Hematological Stem"/>
 <result pre="(HSCT), HIV, and malnourished patients, are at increased risk for" exact="viral" post="infections with high incidences of morbidity and mortality. In"/>
 <result pre="HIV, and malnourished patients, are at increased risk for viral" exact="infections" post="with high incidences of morbidity and mortality. In HSCT"/>
 <result pre="high incidences of morbidity and mortality. In HSCT patients, the" exact="infection" post="risk is increased until immune reconstitution is re-established. Therapy"/>
 <result pre="adenovirus infection. The increased efficacy of Brincidofovir (BCV) against multiple" exact="viral" post="infections, limited toxicity, and oral-administered schedule opens options in"/>
 <result pre="The increased efficacy of Brincidofovir (BCV) against multiple viral infections," exact="limited" post="toxicity, and oral-administered schedule opens options in different resource"/>
 <result pre="Report A 9-year-old girl diagnosed with transfusion-dependent refractory cytopenia of" exact="childhood" post="(RCC) was treated with a T-cell-depleted haploidentical transplantation from"/>
 <result pre="presented with general malaise, weight loss, and vomiting. Concomitant Epstein–Barr" exact="viral" post="(EBV) reactivation, Herpes simplex (HSV) infection, and Human adenovirus"/>
 <result pre="with rituximab and HSV with acyclovir. However, as the HAdV" exact="viral" post="load (VL) increased to 132 × 106 copies/ml, treatment with 5 mg/kg"/>
 <result pre="with concomitant hydration only obtained a moderate decrease in the" exact="viral" post="load (Figure 1). The patient rapidly developed renal toxicity."/>
 <result pre="weekly. This successfully suppressed the VL with significant clinical improvement." exact="Cholestasis" post="developed one week after the start of BCV treatment."/>
 <result pre="after resolution of the cholestasis, clearing the VL in the" exact="absence of" post="immune reconstitution. 2. Discussion HAdV is a non-enveloped double-stranded"/>
 <result pre="types, divided into seven species [1–3]. Maternal antibody protection prevents" exact="infections" post="before 6 months of age, whereafter endemicity is established"/>
 <result pre="but spread, morbidity, and mortality are increased in regions with" exact="limited" post="sanitation such as low- and middle-income countries (LMIC) as"/>
 <result pre="transmission occurs via droplet, feco-oral, and direct spread [5]. After" exact="primary" post="infection the virus remains latent in the lymphoreticular system."/>
 <result pre="occurs via droplet, feco-oral, and direct spread [5]. After primary" exact="infection" post="the virus remains latent in the lymphoreticular system. In"/>
 <result pre="cytotoxic T cells and inadequate clearance, the HAdV caused a" exact="symptomatic" post="viraemia [6, 7]. Other immunocompromised patients (e.g., severe combined"/>
 <result pre="caused a symptomatic viraemia [6, 7]. Other immunocompromised patients (e.g.," exact="severe combined immunodeficiency" post="or HIV-patients) might as well benefit from easily accessible"/>
 <result pre="a symptomatic viraemia [6, 7]. Other immunocompromised patients (e.g., severe" exact="combined immunodeficiency" post="or HIV-patients) might as well benefit from easily accessible"/>
 <result pre="symptomatic viraemia [6, 7]. Other immunocompromised patients (e.g., severe combined" exact="immunodeficiency" post="or HIV-patients) might as well benefit from easily accessible"/>
 <result pre="with a reasonably safe toxic profile [8]. Treatment of HAdV" exact="infection" post="in immunocompromised patients is ineffective without immune reconstitution [6,"/>
 <result pre="Figure 2(a)), and therefore poor results [9]. This might obtain" exact="viral" post="control but hardly ever viral clearance. Cidofovir is most"/>
 <result pre="results [9]. This might obtain viral control but hardly ever" exact="viral" post="clearance. Cidofovir is most effective as prophylaxis with increasing"/>
 <result pre="prophylaxis with increasing titres on stool samples, plasma PCR's or" exact="early onset" post="disease [10]. The side effect profile includes nausea, vomiting,"/>
 <result pre="increasing titres on stool samples, plasma PCR's or early onset" exact="disease" post="[10]. The side effect profile includes nausea, vomiting, myelosuppression"/>
 <result pre="onset disease [10]. The side effect profile includes nausea, vomiting," exact="myelosuppression" post="and severe renal tubulopathies [8]. During treatment the direct"/>
 <result pre="time consuming with complex administration procedures [12]. In LMIC, high" exact="viral infection" post="susceptibilities in patients with HIV, malnutrition, chronic diseases, malignancies,"/>
 <result pre="consuming with complex administration procedures [12]. In LMIC, high viral" exact="infection" post="susceptibilities in patients with HIV, malnutrition, chronic diseases, malignancies,"/>
 <result pre="LMIC, high viral infection susceptibilities in patients with HIV, malnutrition," exact="chronic" post="diseases, malignancies, as well as increasing organ transplantation, family-related"/>
 <result pre="availability is guaranteed. 3. Conclusion BCV can successfully treat HAdV" exact="infection" post="in post-transplant immunocompromised children. Although direct drug costs have"/>
 <result pre="cost savings on hospitalization, staffing, screening, and procedures in multiple" exact="disease" post="profiles makes BCV a promising drug for resource-limited settings."/>
 <result pre="authors have no conflicts of interest to declare. References 1FeuchtingerT.LangP.HandgretingerR.Adenovirus" exact="infection" post="after allogeneic stem cell transplantationLeukemia &amp;amp; Lymphoma200748224425510.1080/1042819060088115717325884 2WallsT.ShankarA.ShingadiaD.Adenovirus: an"/>
 <result pre="increasingly important pathogen in paediatric bone marrow transplant patientsThe Lancet" exact="Infectious" post="Diseases200332798610.1016/s1473-3099(03)00515-212560192 3HeemskerkB.LankesterA. C.van VreeswijkT.et al.Immune reconstitution and clearance of"/>
 <result pre="of human adenovirus viremia in pediatric stem-cell recipientsThe Journal of" exact="Infectious" post="Diseases2005191452053010.1086/42751315655775 4WY IpW.QasimW.Management of adenovirus in children after allogeneic"/>
 <result pre="adenovirus in diarrhoeic children in Tanzania; a case control studyBMC" exact="Infectious" post="Diseases201414110.1186/s12879-014-0666-1 6FeuchtingerT.RichardC.PfeifferM.et al.Adenoviral infections after transplantation of positive selected"/>
 <result pre="in Tanzania; a case control studyBMC Infectious Diseases201414110.1186/s12879-014-0666-1 6FeuchtingerT.RichardC.PfeifferM.et al.Adenoviral" exact="infections" post="after transplantation of positive selected stem cells from haploidentical"/>
 <result pre="updateKlinische Pädiatrie2005217633934410.1055/s-2005-87253016307420 7TaniguchiK.YoshiharaS.TamakiH.et al.Incidence and treatment strategy for disseminated adenovirus" exact="disease" post="after haploidentical stem cell transplantationAnnals of Hematology20129181305131210.1007/s00277-012-1440-322476883 8WoldW. S.TothK.New"/>
 <result pre="horizon for treating adenovirusExpert Opinion on Pharmacotherapy201516142095209910.1517/14656566.2015.108397526330121 9SymeonidisN.JakubowskiA.Pierre-LouisS.et al.Invasive adenoviral" exact="infections" post="in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality"/>
 <result pre="stem cell transplantation: high mortality in the era of cidofovirTransplant" exact="Infectious" post="Disease20079210811310.1111/j.1399-3062.2006.00184.x17461995 10LindemansC. A.LeenA. M.BoelensJ. J.How I treat adenovirus in"/>
 <result pre="immunotherapy for HSCT-associated complicationsFrontiers in Immunology20167p. 50010.3389/fimmu.2016.00500 Figure 1 The" exact="viral" post="load response during the treatment with Cidofovir and Brincidofovir."/>
 <result pre="leads to chain termination as it is incorporated into the" exact="viral" post="DNA. (b) In Brincidofovir, the lipid conjugated form of"/>
</results>
